title: Clinical characteristics and antibiotic susceptibility of viridans streptococcal bacteremia in children with febrile neutropenia.
abstract: OBJECTIVE
  This retrospective study was performed in order to investigate the clinical characteristics and antibiotic susceptibility of viridans streptococcal bacteremia (VSB) in febrile neutropenic children in the context of the increase in incidence and antibiotic resistance of VSB.
  
  
  METHODS
  We conducted this study among neutropenic children with underlying hematology/oncology diseases who were diagnosed with VSB at a single institution from April 2009 to June 2012. Clinical and laboratory characteristics of the children as well as antibiotic susceptibility of the causative viridans streptococci were evaluated.
  
  
  RESULTS
  Fifty-seven episodes of VSB were diagnosed in 50 children. Severe complications occurred in four children (7.0%), and a death of one child (1.8%) was attributable to VSB. Acute myeloid leukemia was the most common underlying disease (70.2% of all cases), and 71.9% of all cases received chemotherapy including high-dose cytarabine. VSB occurred at a median of 13 days (range 8-21 days) after the beginning of chemotherapy, and fever lasted for a median of 4 days (range 1-21 days). The C-reactive protein level significantly increased within a week after the occurrence of VSB (p < 0.001) and the maximum C-reactive protein level showed a positive correlation with fever duration (r = 0.362, p = 0.007). Second blood cultures were done before the use of glycopeptides in 33 children, and negative results were observed in 30 children (90.9%). Susceptibilities to cefotaxime, cefepime, and vancomycin were 58.9, 69.1, and 100%, respectively.
  
  
  CONCLUSIONS
  Severe complications of VSB in neutropenic febrile children were rare. We suggest glycopeptide use according to the results of blood culture and antibiotic susceptibility tests based on the susceptibility to cefepime and the microbiologic response to empirical antibiotic treatment not including glycopeptides in this study.
authors: Department of Pediatrics, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, Republic of Korea.
authors: S B
authors: SB
authors: Han
authors: E Y
authors: EY
authors: Bae
authors: J W
authors: JW
authors: Lee
authors: D G
authors: DG
authors: Lee
authors: N G
authors: NG
authors: Chung
authors: D C
authors: DC
authors: Jeong
authors: B
authors: B
authors: Cho
authors: J H
authors: JH
authors: Kang
authors: H K
authors: HK
authors: Kim
mesh_terms: D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000494:pharmacology; D016470:Bacteremia / Q000188:drug therapy / Q000382:microbiology*; D002648:Child; D002675:Child, Preschool; D064147:Febrile Neutropenia / Q000188:drug therapy / Q000382:microbiology*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008826:Microbial Sensitivity Tests; D012372:ROC Curve; D056910:Republic of Korea; D012189:Retrospective Studies; D013290:Streptococcal Infections / Q000188:drug therapy / Q000382:microbiology*; D034363:Viridans Streptococci / Q000187:drug effects* / Q000302:isolation & purification; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents
references: Ann Intern Med. 1988 Jan;108(1):30-5
references: 3337513
references: Semin Pediatr Infect Dis. 2006 Jul;17(3):153-60
references: 16934710
references: Clin Infect Dis. 1997 Aug;25(2):247-59
references: 9332520
references: Eur J Cancer. 2003 Jun;39(9):1284-9
references: 12763218
references: Lancet. 1995 Jun 24;345(8965):1607-9
references: 7783538
references: Clin Infect Dis. 1999 Sep;29(3):490-4
references: 10530434
references: J Clin Oncol. 2004 Apr 1;22(7):1222-7
references: 15051769
references: Scand J Infect Dis. 1997;29(3):245-9
references: 9255883
references: Clin Infect Dis. 2002 Jun 1;34(11):1524-9
references: 12015700
references: Pediatr Infect Dis J. 2005 Jun;24(6):563-6
references: 15933573
references: N Engl J Med. 1999 Feb 11;340(6):448-54
references: 9971870
references: Clin Infect Dis. 2011 Feb 15;52(4):e56-93
references: 21258094
references: Am J Med. 1986 Aug;81(2):237-42
references: 3526884
references: Korean J Intern Med. 2011 Jun;26(2):220-52
references: 21716917
references: J Antimicrob Chemother. 2005 Apr;55(4):436-44
references: 15722392
references: Pediatr Hematol Oncol. 2003 Sep;20(6):439-44
references: 14631617
references: J Pediatr Hematol Oncol. 2009 Sep;31(9):623-9
references: 19644403
references: Clin Infect Dis. 2007 Nov 15;45(10):1296-304
references: 17968824
references: Pediatr Blood Cancer. 2007 Nov;49(6):774-80
references: 17588233
references: Clin Infect Dis. 1996 Oct;23(4):785-9
references: 8909845
references: Clin Infect Dis. 2004 Jul 15;39 Suppl 1:S25-31
references: 15250017
references: Clin Infect Dis. 2000 Nov;31(5):1126-30
references: 11073739
references: Cytokine. 1998 May;10(5):370-6
references: 9619375
references: Bone Marrow Transplant. 2004 Jan;33(1):79-85
references: 14704660
references: Pediatr Hematol Oncol. 1995 Jul-Aug;12(4):387-92
references: 7577391
references: Lancet. 2007 May 5;369(9572):1553-1564
references: 17482987
references: J Clin Microbiol. 2006 Jan;44(1):160-5
references: 16390964